Stocks · News reference
Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity Risk
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.
Castle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Castle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est